Context: EmblemHealth, Inc., a health insurer, filed a putative class action in April 2025 (see below) accusing Alexion, an AstraZeneca company, of overcharging for its rare disease drug Soliris. EmblemHealth alleged that Alexion enforced five fraudulently obtained patents to keep biosimilars off the U.S. market from at least March 2022 until Amgen and Samsung Bioepis launched in March and April 2025. On December 19, 2025, Judge Brian E.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Mehnaz
Contact Mehnaz, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack